Retrieved January 16, 2012
Comparison Table (Structure, Pathway, Research Classification) Each compounds classification reflects its underlying mechanism rather than a shared fat-loss peptide category: AOD-9604 remains research-stage and inconclusive, GLP-1 S has the most extensive clinical backing of the three, and tesamorelin occupies a narrower but well-documented niche in visceral fat and GH-axis research
The wound healing cascade and GHK-Cu: Normal wound healing occurs in four overlapping phases: Hemostasis clotting Inflammation immune cell recruitment Proliferation new tissue formation Remodeling scar maturation GHK-Cu appears to favorably influence phases 2, 3, and 4 simultaneously: In the inflammatory phase , it reduces pro-inflammatory cytokines (IL-6, TNF-) while preserving necessary immune signaling In the proliferative phase , it stimulates keratinocyte migration and fibroblast proliferation, accelerating epithelial coverage In the remodeling phase , it promotes type I collagen deposition over type III (scar) collagen, leading to better scar outcomes This multi-phase tissue repair activity makes GHK-Cu a compound of interest when studied alongside other regenerative peptides
But how do they stack up against each other
You can also report issues to the medication manufacturer.
(Source 2, 3) Because glutathione is a small peptide made from amino acids, it likely gets broken down in the digestive system instead of absorbed intact
